Historical Valuation
Abcellera Biologics Inc (ABCL) is now in the Fair zone, suggesting that its current forward PS ratio of 18.51 is considered Fairly compared with the five-year average of 9.84. The fair price of Abcellera Biologics Inc (ABCL) is between 3.04 to 8.96 according to relative valuation methord.
Relative Value
Fair Zone
3.04-8.96
Current Price：4.14
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Abcellera Biologics Inc (ABCL) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.19 , the current P/B ratio is approximately -10.38% higher. Relative to its 5-year average P/B ratio of 2.69, the current P/B ratio is about -60.38% higher. Abcellera Biologics Inc (ABCL) has a Forward Free Cash Flow (FCF) yield of approximately -14.91%. Compared to its 3-year average FCF yield of -11.50%, the current FCF yield is approximately 29.72% lower. Relative to its 5-year average FCF yield of -4.82% , the current FCF yield is about 209.24% lower.
P/B
Median3y
1.19
Median5y
2.69
FCF Yield
Median3y
-11.50
Median5y
-4.82
Competitors Valuation Multiple
AI Analysis for ABCL
The average P/S ratio for ABCL competitors is 12.77, providing a benchmark for relative valuation. Abcellera Biologics Inc Corp (ABCL.O) exhibits a P/S ratio of 18.51, which is 44.98% above the industry average. Given its robust revenue growth of 37.62%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ABCL
1Y
3Y
5Y
Market capitalization of ABCL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABCL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ABCL currently overvalued or undervalued?
Abcellera Biologics Inc (ABCL) is now in the Fair zone, suggesting that its current forward PS ratio of 18.51 is considered Fairly compared with the five-year average of 9.84. The fair price of Abcellera Biologics Inc (ABCL) is between 3.04 to 8.96 according to relative valuation methord.
What is Abcellera Biologics Inc (ABCL) fair value?
ABCL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Abcellera Biologics Inc (ABCL) is between 3.04 to 8.96 according to relative valuation methord.
How does ABCL's valuation metrics compare to the industry average?
The average P/S ratio for ABCL's competitors is 12.77, providing a benchmark for relative valuation. Abcellera Biologics Inc Corp (ABCL) exhibits a P/S ratio of 18.51, which is 44.98% above the industry average. Given its robust revenue growth of 37.62%, this premium appears sustainable.
What is the current P/B ratio for Abcellera Biologics Inc (ABCL) as of Jan 09 2026?
As of Jan 09 2026, Abcellera Biologics Inc (ABCL) has a P/B ratio of 1.06. This indicates that the market values ABCL at 1.06 times its book value.
What is the current FCF Yield for Abcellera Biologics Inc (ABCL) as of Jan 09 2026?
As of Jan 09 2026, Abcellera Biologics Inc (ABCL) has a FCF Yield of -14.91%. This means that for every dollar of Abcellera Biologics Inc’s market capitalization, the company generates -14.91 cents in free cash flow.
What is the current Forward P/E ratio for Abcellera Biologics Inc (ABCL) as of Jan 09 2026?
As of Jan 09 2026, Abcellera Biologics Inc (ABCL) has a Forward P/E ratio of -4.76. This means the market is willing to pay $-4.76 for every dollar of Abcellera Biologics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Abcellera Biologics Inc (ABCL) as of Jan 09 2026?
As of Jan 09 2026, Abcellera Biologics Inc (ABCL) has a Forward P/S ratio of 18.51. This means the market is valuing ABCL at $18.51 for every dollar of expected revenue over the next 12 months.